NRx Pharmaceuticals, Inc.
NASDAQ Global MarketTotal Valuation
NRx Pharmaceuticals, Inc. carries a market capitalization of 361,784.00, placing it among publicly traded companies globally. Its enterprise value stands at -5.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 361,784.00 |
| Enterprise Value | -5.78M |
Share Statistics
NRx Pharmaceuticals, Inc. currently has 33.47M shares outstanding.
| Shares Outstanding | 33.47M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 13.32 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
NRx Pharmaceuticals, Inc. maintains a current ratio of 0.29, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -6.76, indicating conservative leverage, while an interest coverage ratio of -18.61 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.29 |
| Quick Ratio | 0.27 |
| Debt / Equity | -6.76 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | -18.61 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -251.79 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 5.00 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
NRx Pharmaceuticals, Inc.'s stock has declined approximately -82.61934% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.06.
| Beta (5Y) | N/A |
| 52-Week Price Change | -82.61934% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.06 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -16.82M, while operating income came in at -17.13M.
| Revenue | 2.29M |
| Gross Profit | 1.16M |
| Operating Income | -17.13M |
| Pretax Income | -24.54M |
| Net Income | -24.54M |
| EBITDA | -16.82M |
| EBIT | -17.13M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
NRx Pharmaceuticals, Inc. holds 6.71M in cash and equivalents against 934,000.00 in total debt, resulting in a net debt position of -6.71M. Total book value stands at -308.29M, with working capital of -17.81M providing operational flexibility.
| Cash & Cash Equivalents | 6.71M |
| Total Debt | 934,000.00 |
| Net Debt | -6.71M |
| Equity (Book Value) | -308.29M |
| Book Value Per Share | N/A |
| Working Capital | -17.81M |
Cash Flow
NRx Pharmaceuticals, Inc. produced -14.93M in operating cash flow over the past twelve months.
| Operating Cash Flow | -14.93M |
| Capital Expenditures | N/A |
| Free Cash Flow | -14.93M |
| FCF Per Share | N/A |
Margins
NRx Pharmaceuticals, Inc. operates with a gross margin of 50.46, reflecting its pricing power and cost economics. The operating margin of -746.88 and net profit margin of -1,070.26 provide insight into operational efficiency.
| Gross Margin | 50.46 |
| Operating Margin | -746.88 |
| Pretax Margin | -1,070.26 |
| Profit Margin | -1,070.26 |
| EBITDA Margin | -733.49 |
Scores
NRx Pharmaceuticals, Inc. posts an Altman Z-Score of -54.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -54.95 |